• Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises (SUSTAIN)

​

• DOVE Study (Eli Lilly): Determining Effects of Platelet Inhibition on Vaso-occlusive Events

​

• R18: Enhancing the Use of Hydroxyurea Using Patient Navigators

​

• EPIC Study (Mast Therapeutics): Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

​

• Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

​

• Understanding Adherence to Prescribed Opioids in Sickle Cell Disease

​

• Enhancing Adherence to Prescribed Opioids Using A Mobile-Based App: A Pilot Study in Non-Cancer Pain

​

• A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia

​

• Improving Sickle Cell Transfusion Practices and Pediatric to Adult Sickle Cell Transitions

​

• RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study

​

• Effects of HQK-1001 in Patients With Sickle Cell Disease

​

• Program for Transition from Pediatric to Adult Care in Sickle Cell Disease

​

• Sickle Cell Personalized Passport for Pain-Guiding Management of a Rare Disease in the Emergency Department

​

• Program for Transition from Pediatric to Adult Care in Sickle Cell Disease

​

• Sickle Cell Disease Treatment Demonstration Program Regional Collaborative for the North East Region (HRSA), December 2014-November 2019
   

• Sickle Cell Personalized Passport for Pain-Guiding Management of a Rare Disease in the Emergency Department